NiRAN Domain Inhibitors for SARS-CoV-2 Mutant Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and treatments for SARS-CoV-2 are challenged by rapid genetic variability and mutation, leading to reduced efficacy against emerging strains, and existing antiviral compounds are insufficiently active against SARS-CoV-2, necessitating new methods to identify effective therapeutics that can target mutant and resistant strains.
Innovation Solution
Targeting the NiRAN-domain of the nsp12 protein in SARS-CoV-2 using compounds that interfere with the UMPylation process, specifically inhibiting the protein-primed RNA synthesis pathway, which is unique to coronaviruses and conserved across strains, thereby preventing viral replication without inducing resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines and treatments are used against SARS-CoV-2, then initial therapeutic efficacy is achieved, but reduced efficacy occurs against emerging mutant strains due to rapid genetic variability
Solution Approach 1:
The patent extracts and targets the NiRAN domain specifically within the nsp12 protein, separating this critical functional region from the rest of the viral polymerase complex. By focusing therapeutic intervention on this isolated domain that is essential for RNA synthesis and highly conserved across variants, the treatment maintains reliability against emerging mutants while avoiding the adaptability problems that affect broader targeting approaches
Solution Approach 2:
The invention applies local quality by targeting a specific functional domain (NiRAN) with distinct characteristics - it is highly conserved across SARS-CoV-2 variants and critical for viral replication. This localized targeting approach ensures that therapeutic compounds interact with a region that maintains consistent structure and function across different strains, thereby preserving efficacy against mutants without requiring broad adaptability
2Productivity
If existing antiviral compounds are administered, then some viral activity is inhibited, but insufficient activity remains against SARS-CoV-2 requiring new therapeutic methods
Solution Approach 1:
The patent employs compounds that act as intermediaries by binding to the NiRAN domain and interfering with the UMPylation process - a specific biochemical reaction where UMP is transferred to nsp8 to prime RNA synthesis. These intermediary compounds disrupt the transfer of UMP from nsp12 to nsp8, effectively blocking the protein-primed RNA synthesis pathway with high reliability and sufficient activity against SARS-CoV-2
3Productivity
If compounds targeting viral replication are used, then viral synthesis is inhibited, but resistance development may occur through mutations
Solution Approach 1:
The NiRAN domain serves multiple critical functions in the viral replication process - it is involved in UMPylation of nsp8, priming of RNA synthesis, and coordination with the RdRp active site. This multi-functionality means that mutations in the NiRAN domain would have profound effects on viral fitness, making it a stable target that is highly conserved across variants and less prone to resistance development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits SARS-CoV-2 replication across mutant strains, maintaining therapeutic efficacy without driving further mutations, as the NiRAN-domain is highly conserved and critical for viral RNA synthesis, ensuring continued effectiveness against evolving viral variants.
Implementation Method 1
a tyrosine hydroxyl group of nsp8 is first covalently labeled with a uridine monophosphate (referred to as 'UMPylation') by the transfer of UTP to nsp8 to yield UMP-nsp8
Implementation Method 2
Nsp12 has been identified in SARS-CoVs as the primary catalytic subunit with RNA-dependent RNA polymerase (RdRp) activity
Data Source
AI summary
Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12). The invention establishes for the first time herein the foundational discovery of the mechanism of action of the NiRAN-domain, and how it can be used in pharmaceutical therapy against SARS-CoV infection, including a SARS-CoV-2 infection, or exposure.